Identification of markers that functionally define a quiescent multiple myeloma cell sub-population surviving bortezomib treatment

Table 1 Characteristics for the patients whose BM samples were tested for BiP levels in CD138+ cells

MM code	Age at diagnosis	Ouant Immunoglobulins and Serum immunofixation at collection	Albumin	LDH	Prior Bortezomib?	Myeloma status at time of Collection
MM16	64	lgG 2371, monoclonal protein in gamma region	4.3	201	no	Stable disease
MM17	59	IgG 282, IgA 5083, IgM 16, Two IgA lambda monoclonal band seen, representing 85 %	3.7	106	yes	Stable disease
MM18	68	IgG 2333, IgA 12, 1gM 20, monoclonal protein seen in gamma region	3.3	175	yes	Progression of Disease (increase in M-spike)
MM19	46	IgG 4656, IgA 27, 1 gM 53, monoclonal protein in gamma region	3.8	142	no	Minimal response/stable disease
MM20	unav	IgG 4099, monoclonal band in gamma region	3.7	121	unav	Stable Disease
MM21	56	IgG 314, 1 gM <5, IgA <5, faint free kappa band	4.7	143	yes	Progression of Disease
MM22	52	IgG 453, 1 gM 7, IgA 132, faint IgG lambda band	2.7	170	yes	partial response/stable disease
MM23	70	lgG 840, IgA 9, 1 gM 9, lgG kappa monoclonal spike seen, representing all of monoclonal protein	4.5	564	yes	Remission (very good partial response)
MM24	57	lgG 255, 1 gM 12, IgA 19, faint free Lambda band seen	3.1	154	yes	Progression of Disease
MM25	39	lgG 188, IgA 10, 1gM 12, Free monoclonal lambda light chain, normal Igs greatly diminished	4.7	601	yes	Progression of Disease
MM26	66	lgG 6589, Iga 8, 1 gM <5, lgG kappa monoclonal representing all of total	3.9	166	yes	Progression of Disease
MM27	54	lgG 5543, IgA 11, 1 gM 19, lgG kappa monoclonal protein	4.1	210	yes	Progression of Disease

ISSN: 1471-2407